Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study

Methamphetamine use disorder is a major public health concern in Australia and globally. GLP-1 medications such as semaglutide (e.g. Ozempic) are approved for diabetes and medication, and may potentially affect craving for other substances apart from food. We do not know if this will help people who use methamphetamine ('ice') to reduce their use. This study will treat people who use methamphetamine with weekly injections of semaglutide. It will provide data on if this is a potentially safe and practical treatment for this group of people.

NCT Number	NCT07509112
Lead Sponsor	Kirby Institute
Conditions	Methamphetamine Use Disorder
Enrollment	40 participants
Start Date	2026-09
Primary Completion	2027-01 (estimated)
Study Completion	2027-03 (estimated)
Updated on ClinicalTrials.gov	2026-06-26